We are live on ! Find out more
BOCH

Blue Owl Capital Holdings Portfolio holdings

AUM $372M
1-Year Est. Return 78.25%
This Fund
S&P 500
This Quarter Est. Return
-2.91%
1 Year Est. Return
+78.25%
3 Year Est. Return
+112.77%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$434M
AUM Growth
-$84.4M
Cap. Flow
-$38.8M
Cap. Flow %
-8.93%
Top 10 Hldgs %
71.48%
Holding
147
New
10
Increased
10
Reduced
15
Closed
68

Top Buys

Rank Stock Value
1
CNDT icon
Conduent
CNDT
+$8.99M
2
TNGX icon
Tango Therapeutics
TNGX
+$8.04M
3
ELDN icon
Eledon Pharmaceuticals
ELDN
+$7.73M
4
KROS icon
Keros Therapeutics
KROS
+$6.24M
5
EYPT icon
EyePoint Inc
EYPT
+$6.21M

Top Sells

Rank Stock Value
1
TQQQ icon
ProShares UltraPro QQQ
TQQQ
+$23.6M
2
TRML
Tourmaline Bio
TRML
+$11.4M
3
LNZA icon
LanzaTech
LNZA
+$5.59M
4
CCC
CCC Intelligent Solutions
CCC
+$5.05M
5
STWD icon
Starwood Property Trust
STWD
+$4.62M

Sector Composition

Rank Sector Weight
1 Healthcare 50.71%
2 Financials 25.62%
3 Technology 21%
4 Consumer Discretionary 2.08%
5 Energy 0.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NCDL icon
1
Nuveen Churchill Direct Lending
NCDL
$609M
$67.8M 15.62%
4,039,553
– –
KVYO icon
2
Klaviyo
KVYO
$5.8B
$44.5M 10.25%
1,078,770
-119,500
-10% -$4.56M
PLRX icon
3
Pliant Therapeutics
PLRX
$65M
$36.5M 8.4%
2,769,199
-235,000
-8% -$3.21M
OBDC icon
4
Blue Owl Capital
OBDC
$5.35B
$30.9M 7.12%
2,045,070
– –
CGEM icon
5
Cullinan Oncology
CGEM
$1.06B
$28.9M 6.65%
2,370,972
+360,000
+18% +$5.17M
CNDT icon
6
Conduent
CNDT
$253M
$22.7M 5.24%
5,625,459
+2,262,437
+67% +$8.99M
TRML
7
DELISTED
Tourmaline Bio
TRML
$21.9M 5.04%
1,079,321
-451,080
-29% -$11.4M
ENGN icon
8
enGene Therapeutics
ENGN
$120M
$21M 4.84%
3,159,975
+101,006
+3% +$784K
EVCM icon
9
EverCommerce
EVCM
$2.14B
$18.1M 4.17%
1,641,929
– –
LRMR icon
10
Larimar Therapeutics
LRMR
$377M
$18M 4.15%
4,653,040
+486,211
+12% +$3.21M
GOCO
11
DELISTED
GoHealth
GOCO
$11.1M 2.57%
83,264
– –
HLLY icon
12
Holley
HLLY
$335M
$9.03M 2.08%
2,990,294
+446,706
+18% +$1.25M
SLRN
13
DELISTED
ACELYRIN
SLRN
$8.74M 2.01%
2,783,946
-10,000
-0.4% -$48.4K
ELDN icon
14
Eledon Pharmaceuticals
ELDN
$255M
$8.07M 1.86%
+1,959,912
New +$7.73M
IRON icon
15
Disc Medicine
IRON
$2.81B
$7.62M 1.76%
120,260
-55,000
-31% -$3.18M
IMA
16
ImageneBio Inc
IMA
$63.4M
$6.71M 1.55%
340,927
– –
CNTX icon
17
Context Therapeutics
CNTX
$56.7M
$6.68M 1.54%
6,357,928
+946,638
+17% +$1.64M
SGMT icon
18
Sagimet Biosciences
SGMT
$435M
$5.96M 1.37%
1,323,877
-350,000
-21% -$1.77M
TNGX icon
19
Tango Therapeutics
TNGX
$4.21B
$5.35M 1.23%
+1,732,152
New +$8.04M
RARE icon
20
Ultragenyx Pharmaceutical
RARE
$2.46B
$4.97M 1.15%
118,238
-45,000
-28% -$2.23M
EYPT icon
21
EyePoint Inc
EYPT
$999M
$4.97M 1.15%
+667,594
New +$6.21M
RPTX
22
DELISTED
Repare Therapeutics
RPTX
$4.51M 1.04%
3,443,659
+71,160
+2% +$212K
ETWO
23
DELISTED
E2open Parent Holdings
ETWO
$4.39M 1.01%
1,650,943
– –
CMPX icon
24
Compass Therapeutics
CMPX
$349M
$4.28M 0.99%
2,954,712
+75,000
+3% +$125K
KROS icon
25
Keros Therapeutics
KROS
$197M
$3.84M 0.89%
242,633
+120,000
+98% +$6.24M
1
2 3 4 5

Similar funds

PC
Promethos Capital Boston, Massachusetts $372M AUM 23.19% 1-Year Est. Return
GIP
Gavilan Investment Partners Burlingame, California $372M AUM 6.04% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
SAAM
Solus Alternative Asset Management Summit, New Jersey $372M AUM 45.33% 1-Year Est. Return
MWM
Mindset Wealth Management Indianapolis, Indiana $372M AUM 50.62% 1-Year Est. Return
AWA
Acumen Wealth Advisors Chattanooga, Tennessee $372M AUM
KP
Kiltearn Partners Edinburgh, United Kingdom $372M AUM 18.16% 1-Year Est. Return
TCM
Thomist Capital Management Houston, Texas $371M AUM 77.62% 1-Year Est. Return

Blue Owl Capital Holdings's Q4 2024 Portfolio in Review

As of Q4 2024, Blue Owl Capital Holdings held 147 positions worth $434M, down 16% from $518M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Blue Owl Capital Holdings withdrew a net $38.8M in Q4 2024, closing 68 positions and reducing 15 holdings. Its most notable exit was ProShares UltraPro QQQ, an estimated $23.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 51% of assets, down from 53% a quarter earlier, followed by Financials and Technology.

Against the trend, Blue Owl Capital Holdings opened a new position in Tango Therapeutics worth $5.35M.

  • Blue Owl Capital Holdings's largest Q4 2024 buy was Tango Therapeutics: 1,732,152 shares worth $5.35M.
  • Blue Owl Capital Holdings added most to Conduent in Q4 2024, an estimated $8.99M increase.
  • Blue Owl Capital Holdings's biggest Q4 2024 reduction was Tourmaline Bio, cutting an estimated $11.4M.
  • Blue Owl Capital Holdings fully exited ProShares UltraPro QQQ in Q4 2024, selling an estimated $23.6M.
  • Blue Owl Capital Holdings's ten largest holdings make up 71% of its $434M portfolio in Q4 2024.
  • Blue Owl Capital Holdings opened 10 new positions and closed 68 in Q4 2024.
  • Blue Owl Capital Holdings's portfolio value fell 16% quarter-over-quarter to $434M.

Based on Blue Owl Capital Holdings's 13F filing for Q4 2024, filed 14 Feb 2025.